We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch®, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.
Our Publications on EpiSwitch®
A novel epigenetic blood test to monitor minimal residual disease in high-risk neuroblastoma.
Petrie, K., et. al.,
Cancer Research
April 6, 2013
http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-87
Breast cancer: development of early non-invasive diagnostics to reduce disease mortality and psychological outcomes.
Jeznach, M., et.al.,
Psychoonkologia
February 3, 2013
http://www.termedia.pl/Breast-cancer-development-of-early-non-invasive-diagnostics-to-reduce-disease-mortality-and-psychological-outcomes,63,21815,0,1.html